The advent of new biologic medicines in the past 25 years has been transformational, introducing powerful new treatments for a range of autoimmune disorders. But these drugs don’t help all patients and some who do respond find they need greater efficacy. Most of those biologics are monoclonal antibodies engineered to hit a single target. Startup Dualitas Therapeutics aims to achieve better outcomes by hitting two targets with a single drug.

Dualitas’s research has yielded two bispecific antibodies that are its lead programs, both in oreclinical development for prevalent immunological conditions. The San Francisco-based startup also has an emerging pipeline based on discoveries from its platform technology. As Dualitas continues to make progress, the startup launched from stealth this we

See Full Page